Clinical Trial: Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07046182) titled 'Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight' on June 22.

Brief Summary: To observe the efficacy and safety of the CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma.

Study Start Date: Oct. 21, 2023

Study Type: INTERVENTIONAL

Condition: Angioimmunoblastic T-cell Lymphoma (AITL)

Intervention: BIOLOGICAL: CEP + Dasatinib + Azacitidine

CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: ...